

## Inverse QSAR: Reversing Descriptor-Driven Prediction Pipeline Using Attention-Based Conditional Variational Autoencoder

William Bort, Daniyar Mazitov, Dragos Horvath, Fanny Bonachera, Arkadii Lin, Gilles Marcou, Igor Baskin, Timur Madzhidov, Alexandre Varnek

### ▶ To cite this version:

William Bort, Daniyar Mazitov, Dragos Horvath, Fanny Bonachera, Arkadii Lin, et al.. Inverse QSAR: Reversing Descriptor-Driven Prediction Pipeline Using Attention-Based Conditional Variational Autoencoder. Journal of Chemical Information and Modeling, 2022, 62 (22), pp.5471-5484. 10.1021/acs.jcim.2c01086 . hal-04244025

## HAL Id: hal-04244025 https://hal.science/hal-04244025

Submitted on 16 Oct 2023


**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Inverse QSAR: Reversing Descriptor-Driven Prediction Pipeline Using Attention-Based Conditional Variational Autoencoder

<sup>3</sup> William Bort, Daniyar Mazitov, Dragos Horvath, Fanny Bonachera, Arkadii Lin, Gilles Marcou, <sup>4</sup> Igor Baskin, Timur Madzhidov, and Alexandre Varnek<sup>\*</sup>

5 ABSTRACT: To better formalize the notorious inverse-QSAR 6 problem (finding structures of given QSAR-predicted properties) is 7 considered in this paper as a two-step process including (i) finding 8 "seed" descriptor vectors corresponding to user-constrained QSAR 9 model output values and (ii) identifying the chemical structures 10 best matching the "seed" vectors. The main development effort 11 here was focused on the latter stage, proposing a new attention-12 based conditional variational autoencoder neural-network archi-13 tecture based on recent developments in attention-based methods. 14 The obtained results show that this workflow was capable of 15 generating compounds predicted to display desired activity while



16 being completely novel compared to the training database (ChEMBL). Moreover, the generated compounds show acceptable 17 druglikeness and synthetic accessibility. Both pharmacophore and docking studies were carried out as "orthogonal" *in silico* validation 18 methods, proving that some of *de novo* structures are, beyond being predicted active by 2D-QSAR models, clearly able to match 19 binding 3D pharmacophores and bind the protein pocket.

#### 1. INTRODUCTION

<sup>20</sup> Predictive quantitative structure—activity/property relations <sup>21</sup> (QSAR/QSPR)<sup>1</sup> are regression or classification models that <sup>22</sup> are able to compute, upon input of a molecular structure, an <sup>23</sup> estimate of the activity/property value the compound is <sup>24</sup> expected to display. One may formulate the above as activity = <sup>25</sup> f(structure), where function f needs first to be calibrated in <sup>26</sup> order to have f(structure) returning accurate approximations of <sup>27</sup> known activity values. If the above holds, then *inverse mapping* <sup>28</sup> would allow to retrieve the "optimal" chemical structure(s), <sup>29</sup> maximizing the expectancy of having an activity matching the <sup>30</sup> input argument, that is, the desired activity level needed to <sup>31</sup> achieve success in the current research project.

Since the first pioneering linear regression model by Hansch and Leo,<sup>2</sup> procedures to "fit," for example, machine learn f(structure), have progressed to the point of routine calibration for nonlinear models based on a plethora of machine learning methods (support vector machines, partition trees, neural retworks—to cite only the most popular<sup>3-7</sup>).

Typically, the *structure* argument in f(structure) is the 39 molecular graph with vertices colored by chemical elements 40 and edges colored by bond types. Since f(structure) returns a 41 real number, it is obvious that the information content of the 42 input molecular graph could first be translated in this process 43 into some purely numerical representation—a vector of N real 44 numbers  $\vec{D}$  known as the "molecular descriptor vector." In 45 classical QSAR, the two formal steps, descriptor calculation  $\vec{D}$  =  $\theta$ (structure) and model fitting, activity =  $\mu(\vec{D})$  are clearly 46 separated into successive steps, and hence activity =  $\mu(\theta$ - 47 (structure)) = f(structure). Hence, the inverse QSAR problem 48 may be conceptualized as a succession of two formal steps:<sup>8-10</sup> 49

- 1. finding descriptor vectors ("seed vectors") matching the 50 desired activity level:  $\vec{D} = \mu^{-1}(\text{activity})$  51
- 2. finding the structures that correspond to the  $\vec{D}$  above: 52 structure =  $\theta^{-1}(\vec{D})$  53

Since  $\mu: \mathbb{R}^N \to \mathbb{R}$ , searching extremal points of  $\mu(\vec{D})$  is a 54 standard optimization problem, and albeit solving may prove 55 challenging when  $\mu$  is highly nonlinear or if *N* is large, this step 56 of inverse QSAR is conceptually an easy one. 57

By contrast, step 2 is both technically and conceptually 58 hard—to the point that, until recently, the typical way to 59 discover molecules with activity values matching a desired 60 activity level is to enumerate candidate structures and apply, to 61 each, the QSAR model until all input candidates were herewith 62 "virtually screened<sup>11,12</sup>" or until enough events  $f(\text{structure}) \approx 63$  desired activity occurred, for example, "virtual hits" were 64

Received: August 27, 2022

65 found. Virtual screening (VS), however, is limited by the 66 choice of candidate structures either from public/commercial 67 databases or from user-designed virtual libraries. In contrast to 68 systematic VS, sampling techniques of chemical structures 69 consider molecular structure as evolvable.<sup>13–15</sup> This is *de novo* 70 design,<sup>16–23</sup> which fundamentally differs from VS by the fact 71 that structures are not a predefined library but are generated 72 and/or modified "on the fly" by some automated molecular 73 structure editor.

The recent advent of deep neural networks (DNNs), able to 74 75 extract information from arbitrary "brute" data and herewith 76 learn to recognize patterns, had a major impact in the field of 77 QSAR.<sup>24–28</sup> The idea of DNNs is mimicking a human brain in 78 which neurons communicate by generating and passing signals. 79 Along with many applications of DNNs, Rana et al.<sup>29</sup> reviewed 80 the application of the simplest example of DNN models-81 multilayer perceptron (MLP)—to disease diagnostics. MLP 82 was also shown as a method to build successive QSAR 83 models.<sup>30</sup> Later, parsing a chemical structure given in the form 84 of a SMILES string by DNNs using the natural language 85 processing technique was proposed as a new approach for 86 QSAR model training.<sup>31</sup> This success was not the end, and 87 soon graph convolutional networks were proposed as a 88 replacement of recurrent neural networks (RNNs) in QSAR 89 modeling.<sup>32</sup> As the research domain is in full effervescence, an 90 exhaustive overview of already envisaged DNN architectures is 91 beyond the scope of this article. The reader is encouraged to 92 access the most recent reviews.<sup>33</sup>

<sup>93</sup> Some DNN architectures, namely, autoencoders, relate <sup>94</sup> input structure (simply rendered as SMILES<sup>34</sup>) to activity <sup>95</sup> within a unique computational framework, apparently <sup>96</sup> bypassing the need for molecular descriptors in QSAR. *De* <sup>97</sup> *facto*, SMILES string encoder architectures first translate <sup>98</sup> structure to a "latent" real vector  $\vec{L}$ , which the associated <sup>99</sup> decoder would use to regenerate the SMILES. Thus,  $\vec{L}$  is <sup>100</sup> nothing but a machine-generated molecular descriptor vector. <sup>101</sup> Therefore, the decoder is a deep-learning-based model based <sup>102</sup> on latent space descriptors  $\vec{L}$  implicitly allowing for a solution <sup>103</sup> to the inverse problem.

So far, the majority of QSAR models are still based on 104 105 classical, human expert-designed descriptors. This is first due 106 to historical reasons, latent space descriptors L being very new. 107 However, expert-designed descriptors D may still have a key 108 advantage over the former (such as atom order invariance, 109 which may be an issue in  $\vec{L}$  spaces—and their support of 110 relatively small training sets in contrast to "big data"-dependent 111 DNN approaches). So far, only a few attempts to convert 112 arbitrary descriptor space  $\vec{D}$  back to structure have been 113 described. One work<sup>35</sup> reports two distinct RNN-driven 114 approaches labeled PCB (physchem-based) and FPB (finger-115 print-based). The former inputs a vector of predicted physico-116 chemical properties (including a QSAR-predicted bioactivity 117 value) to generate SMILES strings of compounds matching 118 these properties. The latter uses Morgan fingerprints for input. 119 Similarly, a transformer architecture has been implied to 120 "translate" various classical chemoinformatics fingerprints back 121 to structure.<sup>36</sup> Both works can be considered as examples of 122 "hard" inverse QSAR approaches and were successfully used to 123 generate structures in the neighborhood of known actives. 124 However, they stopped short of coupling "easy" and "hard" 125 QSAR problems in order to investigate how their approaches 126 would cope with input vectors corresponding to optima of the 127 QSAR landscape, not to already known molecules.

For the above reasons, the current contribution wishes to 128 explore the feasibility of a genuine solution for the inverse 129 QSAR problem for models based on classical, expert-defined 130 molecular descriptors. The core of this work consists in the 131 development of an attention-based conditional variational 132 autoencoder (ACoVAE) based on transformer architecture. 133 Given the seed vectors of ISIDA fragment descriptors, the 134 ACoVAE generates corresponding molecules. 135

We have used two types of in-house generated QSAR 136 models of ABL tyrosine kinase 1 (CHEMBL1862) activity: 137

1. Support vector regression (SVR) models for the <sup>138</sup> inhibition constant ( $pK_i$ ) using  $\vec{D} = \text{ISIDA}^{37,38}$  circular <sup>139</sup> fragment counts. Seed vectors prepared with the help of <sup>140</sup> a genetic algorithm used to sample  $\vec{D}$  space with <sup>141</sup> predicted  $pK_i$  value as fitness. <sup>142</sup>

Additionally, the descriptor vector of the molecule 143 possessing the highest affinity ("lead molecule" LM) from 144 the CHEMBL1862 set was also used as a seed vector. 145

2. Generative topographic mapping (GTM)-based predic- 146 tive activity class landscapes using the "universal" map<sup>39</sup> 147 based on  $\vec{D}$  = force field-type colored<sup>40</sup> ISIDA atom 148 sequence counts. Sampling of  $\vec{D}$  was performed around 149 the coordinates of active-enriched nodes of the land- 150 scape. 151


The inverse QSAR problem is considered solved if (i) the 152 obtained structures are valid and chemically feasible and (ii) 153 the obtained structures are submitted to classical forward 154 QSAR model prediction and return conveniently high activity 155 values. 156

Here, the ultimate goal was to obtain *de novo* structures that 157 are perceived by a QSAR model to be highly active—whether 158 they really are active or not is a question of underlying model 159 quality, not of the quality of the inverse QSAR approach. 160 Nevertheless, an alternative orthogonal *in silico* validation of 161 these structures as ligands of the considered targets has been 162 performed by pharmacophore analysis with the LigandScout<sup>41</sup> 163 program and by docking using both LeadIT<sup>42</sup> and S4MPLE<sup>43</sup> 164 approaches. 165

#### 2. METHODS

**2.1. ACOVAE.** The proposed ACoVAE transformer model 166 is shown in Figure 1. It consists of three main parts: 167 fl

- During the training procedure, a GRU-based encoder 168 parametrizes a random latent vector distribution based 169 on the training set SMILES. Hyperspherical distribution 170 with zero mean and variance equal to 1 is used as target 171 latent vector distribution; 172
- (2) A condition vector encoder uses a grouped linear 173 transformation (GLT) layer<sup>44</sup> to transform initial 174 descriptor vectors to a conditional latent vector; 175
- (3) A standard autoregressive multihead attention decoder<sup>45</sup> 176 translates from condition and random latent vectors to 177 SMILES. A more detailed architecture of the network is 178 given in Supporting Information, Figures S1 (training 179 stage) and S2 (inference stage). During the training, a 180 SMILES strings and their corresponding descriptor 181 vectors are used to train the ACoVAE. A reparamete- 182 rization trick for latent vector sampling is used to train 183 the network end-to-end. In the inference stage, the latent 184 vector is sampled from a prior (0, 1) hyperspherical 185 distribution, and a desired descriptor vector is used as 186



**Figure 1.** General scheme of the ACoVAE architecture used in this study. The GRU-based encoder (top left) parametrizes SMILES into latent vectors following a hyperspherical distribution, which is used upon inference for random sampling. The descriptor vector which is used as a condition in the generation is embedded by a GLT layer (top right). Autoregressive transformer is used to decode random latent vectors and combined conditions into SMILES strings. A detailed representation of all three networks is given in the Supporting Information.

condition. Based on the random and condition vector, 187 the decoder generates a wanted SMILES. Notice, that 188 alternative SMILES for a given condition descriptor 189 vector can be generated both (i) by running inference 190 stage with different random vectors sampled from a prior 191 distribution and (ii) by sampling different text strings 192 using categorical sampling from token probabilities 193 predicted by the transformer for a given random and 194 condition vector. 195

The proposed architecture of the ACoVAE transformer was inspired by the one proposed by Lin *et al.*<sup>46</sup> In a similar way, a srandom latent vector is fed as a START token. However, substantial changes were introduced which helped us to achieve better performance. In our architecture, a random latent vector is encoded directly using a GRU, while Lin *et al.* used a trick with a priori undefined random distribution

parameterized by a separate network. Additionally, a hyper- 203 spherical uniform distribution was preferred to a standard 204 Gaussian one because during the tuning stage, the former 205 performed better. A von Mises-Fisher distribution is 206 commonly used for sampling from hyperspherical uniform 207 distribution<sup>47</sup> with the reparameterization trick. However, we 208 found that the power spherical distribution<sup>48</sup> used instead of 209 von Mises-Fisher one allows a speeding up of the learning 210 process without loss of the performance. Application of a GLT 211 transformation layer<sup>49</sup> better translates the descriptor vector 212 into the internal representation used by the decoder network 213 than MLP. Finally, inspired by the GELU approximation,<sup>50</sup> 214 new activation function FTSwishG resulted from some 215 modifications of the previously reported FTSwish<sup>51</sup> was used 216 throughout the ACoVAE network 217

 $FTSwishG = RELU(x) \times sigmoid(1.702x) - 0.2 \qquad (1)_{218}$ 

According to our tests, it gives better results compared to the 219 ReLU, GeLU, and FTSwish activation functions. In such a 220 way, our ACoVAE transformer architecture is a novel one, 221 having only a few in common with the one proposed by Lin *et 222 al.*<sup>46</sup> The designed architecture is implemented using the 223 TensorFlow framework and can be readily retrained for other 224 descriptor types. It is available on our GitHub storage https:// 225 github.com/Laboratoire-de-Chemoinformatique/ACoVAE. 226

2.2. SVR Models. A series of ligands for ABL tyrosine 227 kinase (CHEMBL1862) from the ChEMBL v.23 database was 228 standardized using a protocol reported by Sidorov et al.<sup>39</sup> SVR 229 models for thermodynamic instability constants of protein- 230 ligand complexes (pKi) were generated using the evolutionary 231 *libsvm* model tuner,<sup>52</sup> which supports selection of the best 232 suited descriptor space yielding to best performance models as 233 a key hyperparameter. The best-suited ISIDA fragmentation 234 schemes were defined together with the SVR-specific 235 parameters (kernel type, cost,  $\gamma$ , etc.) optimizing model quality. 236 The models were built on a training set containing 739 237 molecules and validated on a test set of 82 molecules. The test 238 set data were collected from recent publications posterior to 239 model training. The best model relies on IIRAB-1-3 ISIDA 240 fragment count descriptors (7372 atom-centered fragments 241 with a radius of 1 to 3 atoms with restricted fragmentation) 242 and the Gaussian kernel option. It displayed a reasonable 243 performance in cross-validation ( $R^2 = 0.79$  and RMSE = 0.70) 244 and on the test set  $(R^2 = 0.80 \text{ and } RMSE = 0.67)$ . 245

Computation of the "optimal" seed vectors has been 246 confided to an evolutionary heuristic browsing through the 247 D space in search of vectors maximizing computed pK<sub>i</sub> values. 248 The "chromosome" of the approach is a 20-dimensional 249 integer vector in which loci may contain either zero or a 250 number denoting a training set compound. The vector 251 encoded by such a chromosome is taken as the mean  $\langle D \rangle$  of 252 descriptor vectors of the training set compounds mentioned in 253 the chromosome (a compound may be mentioned several 254 times in different loci, which amounts to increasing its weight 255 in the computed average). The fitness score of the 256 chromosome is nothing but the corresponding  $pK_i = 257$  $SVR(\langle D \rangle)$  to be maximized. Hence, the evolutionary algorithm 258 is bound to find, by applying cross-over and mutation 259 operators, chromosomes enumerating optimal sets of training 260 set compounds, with the property that the centroid of the 261 descriptor vector of the set is predicted to correspond to high 262 affinity values. The procedure was applied for each SVR model 263 for 150,000 generations. Sampled "high-affinity"  $\langle D \rangle$  values 264 265 were used as the condition vector for the ACoVAE decoder. 266 Details about evolutionary model building can be found in our 267 publication,<sup>52</sup> which also provides instruction on how to obtain 268 and download that tool. Here, it was used with default setup, 269 meaning 12-fold-repeated three-fold cross-validation (with 270 steadily reshuffled cross-validation tiers at every iteration). 271 The model fitness score was the mean cross-validated 272 determination coefficient  $\langle Q^2 \rangle$  penalized by 1 standard 273 deviation, fitness =  $\langle Q^2 \rangle - \sigma(Q^2)$ .

2.3. GTM Landscape-Driven Models. GTM is a 274 275 dimensionality reduction technique developed by Bishop et 276 al.<sup>53,54</sup> The method performs a nonlinear projection of an N-277 dimensional space onto a 2D latent space. The former 278 corresponds to the descriptor space, where each molecule is 279 defined by an N-dimensional molecular descriptor vector. The 280 2D latent space corresponds to a manifold which is defined by 281 a set of radial basis functions and evaluated on sample points 282 called "nodes." Simply put, the manifold can be seen as a 283 rubber band that can be folded in N-dimensions during 284 training to fit the data distribution in a way maximizing its 285 coverage of the space zones populated by relevant items (the 286 "frame set"). Any compound can subsequently be projected on 287 the manifold. For visualization purposes, the manifold is "unfolded" into a 2D plane, organizing the nodes into a square 288 289 grid. GTM is a probabilistic method, meaning that compounds 290 are fuzzily projected on all nodes of the manifold. As such, an 291 item is associated with ("resident in") each node with different 292 probabilities. The sum of the probabilities-technically named 293 responsibilities—over all nodes of the manifold equals 1. In 294 practice, this means that one compound will be defined by a 295 responsibility "pattern" potentially involving several nodes 296 instead of being confined to one node only. When projecting 297 compounds of experimentally known properties, neighborhood 298 behavior<sup>55</sup> (NB) compliance implies that residents of the same 299 node should have related property values, so that the node may 300 be seen to "represent" that local average property, and 301 "colored" accordingly. Resulting property "landscapes" are 302 nothing but NB-driven QSAR models: the property of any 303 external item can be predicted from the "local color" of the 304 landscape zone onto which it is projected. In this work, the 305 fuzzy class landscapes (monitoring the likelihood to classify as 306 "active" with respect to a target) were employed. They were 307 based on the previously published<sup>56</sup> universal map #1 308 (UM1)-the first of a series of GTMs parameterized (using 309 ChEMBL data), such as to maximize their "polypharmaco-310 logical competence," that is, their ability to host a large battery 311 of highly predictive fuzzy class landscapes associated with 312 diverse biological targets. Note that landscape-based QSAR 313 models are parameter-free (the landscapes are built by 314 projection of existing structure-activity data on the given 315 manifold in an unsupervised manner). Therefore, landscape-316 based OSAR models are implicitly available as soon as the 317 supporting structure-activity data are available.

The structure-activity data set associated with the 319 CHEMBL1862 target was projected on the manifold of the 320 first universal map  $UM1^{56}$  and was seen to "spontaneously" 321 segregate into zones populated predominantly by "actives" and 322 "inactives," respectively. This map was built based on ISIDA<sup>40</sup> 323 atom sequence counts with a length of two to three atoms 324 labeled by CVFF force field types and formal charge status (IA-325 FF-2-3-FC). Recall that construction of activity landscapes on 326 a given GTM manifold is not supervised but a purely 327 deterministic procedure. The separation proficiency of the considered manifold was obtained by repeated leave-1/3-out 328 cross-validation, in which iteratively two-third of the items are 329 projected on the map in order to "color" the activity class 330 landscape, whereas the remaining one-third of compounds *a* 331 *posteriori* projected onto that landscape and have their activity 332 classes assigned on basis of their residential zones in the 333 landscape. Cross-validated balanced accuracy was 0.78, 334 significantly above the randomness threshold of 0.5. The 335 structure—activity dataset is herewith proven to be robust and 336 modelable by both machine-learning (SVR) and neighborhood 337 analysis-based mapping.

Activity class landscape for CHEMBL1862 was used to identify zones in the chemical space in which "active" compounds tend to cluster preferentially. Note that the label "active" was assigned to compounds with the ~25% highest affinity values according to the initial automated data curation procedure used for universal map fitting. The GTM nodes *n* in which active compounds were seen to preferentially reside were identified as key points if

$$\frac{\sum_{c \in \text{Actives}} R_{cn}}{\sum_{\text{all } c} R_{cn}} \gg \frac{N_{\text{Actives}}}{N_{\text{all}}} \tag{2}_{347}$$

 $R_{cn}$  represents the responsibility of compound *c* with respect 348 to node *n*, summed over actives (numerator) and over all 349 training compounds (denominator), with the ratio represent- 350 ing the fuzzy-logic propensity to expect an active "resident" in 351 node *n*. This propensity should be much higher than the 352 baseline propensity to encounter an active throughout the 353 training set (top nodes were selected according to the ratio of 354 summed responsibilities). Coordinates of these key nodes 355 correspond to vectors in ISIDA descriptor chemical space 356 zones expected to harbor active compounds. The Gaussian 357 neighborhoods of key node vectors were sampled by 358 generating a multidimensional Gaussian distribution with a 359 width of w = 0.05. Several vectors were generated from the 360 initial node vector using this method.

2.4. Solution of Inverse QSAR Problem: The ACoVAE 362 Algorithm. Sampling with the ACoVAE transformer is 363 accomplished by giving a descriptor vector to the trained 364 decoder part of the model. Each descriptor vector, which 365 corresponds to the "condition" part of the ACoVAE, is 366 combined with a batch of random vectors from a power 367 spherical distribution, which serves as the basis for the latent 368 space. Each descriptor vector/random latent vector combina- 369 tion returns a sample of generated SMILES. Categorical 370 sampling is the preferred method of generation since it allows, 371 for the same input, to explore different possibilities, thus 372 maximizing the generative "coverage." Therefore, the batch of 373 latent vectors returns a batch of generated SMILES. For 374 example, for one descriptor vector concatenated with 200 375 different sampled random vectors with a batch size of 512, the 376 algorithm returns  $200 \times 512 = 102,400$  generated SMILES. In 377 such a way, a given descriptor vector can be used several times 378 leading to different SMILES. In-house CGRtools<sup>57</sup> software is 379 used to verify the validity of the generated text string, directly 380 removing any incoherent or incorrect SMILES. 381

The following parameters were analyzed when monitoring 382 the pertinence of the inverse QSAR approach: 383

1. Validity = #valid SMILES/#all generated text strings, 384 which measures success to generate a syntactically valid 385 SMILES string (assessed by CGRtools), starting from 386 the input "high-affinity"  $\langle \vec{D} \rangle$  vectors. 387

- Feasibility assessing chemical feasibility and drug-likeness
   according to Ertl<sup>58</sup> and QED<sup>59</sup> indices.
- 390 3. Novelty. A compound generated with ACoVAE is
   391 considered "novel" if it is not contained in the training
   392 database.

A coherence between the ISIDA descriptor vector recalculated for the generated SMILES string and the input vector at the source of that SMILES was assessed using the Tanimoto similarity score.

**2.5. Filtering of Nonvalid SMILES Strings.** During the sampling procedure, output SMILES were parsed and sys standardized using CGRtools. Then, they were transformed 400 into Kekulé form followed by verification of valences. If no 401 error detected, the SMILES strings were rearomatized and 402 then written to the output. Failure of any step in this workflow 403 leads to discarding the given text string as invalid SMILES.

#### 3. RESULTS AND DISCUSSION


3.1. Finding Candidate Descriptor Vectors Associated 404 405 with High Affinity. For the SVR model, the evolutionary 406 sampler of the ISIDA descriptor space outlined in Section 2.2 407 is very fast to visit "high-affinity"  $\langle \vec{D} \rangle$  values. Points in the 408 ISIDA descriptor space corresponding to predicted  $pK_i$  values 409 close to the ones of the most active compounds included in the 410 training set can be discovered in matter of tens of minutes on 411 Linux workstations with the following specification: Intel Xeon 412 Silver 4214 2.20 GHz, 48 cores, 64 GB RAM, Ubuntu 18.04.6 413 LTS. However, the discovery of points with activities predicted 414 to be better than the one of the best training compounds was 415 never achieved despite of the total run times of the order of 48 416 h, resulting in >150 K visited  $\langle D \rangle$  values. On the one hand, it is 417 not clear whether such points may actually exist—SVR may 418 suffer (in particular when based on the Gaussian kernel) from 419 the "regression towards the mean" effect, consisting of 420 systematic underestimation of high and overestimation of 421 low property values. Moreover, it is even less likely that points 422 where the SVR model nevertheless predicts a value beyond the 423 largest observed  $pK_i$  would actually be located within the 424 "fragment control bounding box" defining the applicability 425 domain<sup>54</sup> (AD) of the model. Given the fact that herein visited  $426 \langle D \rangle$  values are generated as means of descriptor vectors of 427 randomly selected subsets of compounds, these points are 428 guaranteed within the bonding box AD (each vector element 429  $D_i$  will be larger or equal than the minimal and, respectively, 430 smaller or equal than the maximal  $D_i$  value ever encountered 431 within the training set). Third, the top affinities for all these 432 targets are already within the 0.1 nM range-discovery of 433 significantly more potent molecules is extremely unlikely in 434 this context. Therefore, the five visited  $\langle \vec{D} \rangle$  values correspond-435 ing to the highest predicted  $pK_i$  scores (comparable but not 436 better than the affinity of the most active compound) were 437 used to tackle the inverse QSAR problem (see Figure 2).

438 As a complementary study to the inverse-SVR descriptor 439 selection, the most active ChEMBL compound shown in Table 440 2 (compound A) was selected as a seed to show the difference 441 between the generation from optimized vectors and a real 442 active molecule.

f2.

f3

For the GTM-based activity class predictors, two nodes that 444 were most highly enriched in "active" residents were selected, 445 as represented in Figure 3. Candidate descriptor vectors were 446 obtained by augmenting the D space coordinates of these 447 nodes with Gaussian noise as described in the Methods section



**Figure 2.** Distribution of  $pK_i$  for the compounds used to train the model. The dotted line renders the distribution of predicted  $pK_i$  for the vectors of the final population emerging from the evolutionary sampling approach.





Figure 3. Selected nodes for target ChEMBL1862 on the fuzzy activity class landscape where color encodes the relative populations of actives (class 2, red when pure) vs inactives (class 1, blue when pure). Intermediate color design nodes with residents of both classes in various proportions. Numbers of the node are represented.

(see 2.3). Projection of these seed vectors on the landscapes 448 below unsurprisingly assigns quasi-unitary responsibility values 449 to their "source" nodes, implicitly qualifying them as "probable 450 actives." 451

**3.2.** ACoVAE Calibration Results. Two distinct ACo- 452 VAEs were trained—one for each relevant ISIDA descriptor 453 space:<sup>40</sup> IIRAB-1-3 for the inverse-SVR problem and IA-FF-2- 454 3-FC for the inverse-GTM challenge. Each training set 455 contained the same 1,540,615 compounds from ChEMBL- 456 23, standardized using ChemAxon<sup>60</sup> standardizer, following 457 the procedure implemented on the VS server of the Laboratory 458 of Chemoinformatics in the University of Strasbourg (http:// 459 infochim.u-strasbg.fr/webserv/VSEngine.html). The following 460 standardization steps were applied: (i) dearomatization and 461 final aromatization according to the "basic" setup of the 462

463 ChemAxon procedure (heterocycles like pyridone are not 464 aromatized), (ii) dealkalization, (iii) conversion to canonical 465 SMILES, (iv) removal of salts and mixtures, (v) neutralization 466 of all species, except nitrogen(IV), and (vi) generation of the 467 major tautomer with ChemAxon. This resulted in 1,540,615 468 unique, stereochemistry-depleted SMILES strings used for 469 training (stereochemical information was removed because the 470 herein used molecular descriptors do not capture it).

471 Model training was done for 100 epochs and lasted for about 472 30 h on a QUADRO RTX 6000 graphic card. The loss 473 function tends to stabilize early during training as shown in 474 Figure 4; however, the model continues to learn as character-



**Figure 4.** Training metrics for the ACoVAE transformer model based on ISIDA descriptors. "Loss" is the loss function of the model. "Masked accuracy" corresponds to the character-specific reconstruction rate. "Reconstruction rate" corresponds to the full SMILES string reconstruction rate.

475 specific reconstruction rates and pure reconstruction rates 476 continue to grow. Arguably, the model could be trained for 477 somewhat longer since the reconstruction rate (*val\_rec\_rate*) 478 has seemingly not reached a plateau at 100 epochs. However, 479 we believed that the achieved accuracy—some 50% 480 reconstruction rate and 98% character-specific reconstruction 481 rate, was sufficient for the model acceptance. Notice that 482 variational autoencoders have a tendency for lower recon-483 struction rates than their deterministic counterparts because of 484 the element of randomness introduced by sampling latent 485 vectors from a given distribution instead of having 486 deterministic latent vectors.

487 **3.3. Inverse QSAR Results.** *3.3.1. Inverse-SVR and* 488 Inverse-Lead Compounds. According to Table 1 displaying

Table 1. Performance of the ACoVAE Transformer Modelfor the CHEMBL1862 Target When Sampling from SeedDescriptor Vectors from Different Sources

seed vector source	number (percentage) of valid compounds	number (percentage) of unique compounds	novelty compared to ChEMBL (%)	predicted active <sup>a</sup> (%)
SVR	12,432 (2.43%)	6,899 (55.49%)	100	48.6
GTM	70,684 (13.8%)	61,342 (86.78%)	99.98	6.9
lead molecule	23,559 (4.60%)	7,600 (32.26%)	99.95	41.6


""Predicted active" implies predicted  $pK_i > 7$  by the SVR model. This latter is more stringent than GTM landscape-based predictions, which positions a vast majority of inverse-GTM compounds close to their "source" nodes and herewith classifies them as "actives." various quality criteria of inverse-SVR compounds, the low 489 success rate in the sampling procedure can be mitigated if we 490 consider the time factor. Sampling of 512.000 SMILES strings 491 (using 5 conditional vectors corresponding to the 5 vectors of 492 highest activity predicted by the SVR model) resulting in 6899 493 valid, unique candidates takes only about 4 to 5 h on a 494 QUADRO RTX 6000 GPU. Comparing lead molecule 495 sampling to inverse-SVR sampling shows that both perform 496 similarly in terms of unique valid compounds and activity 497 prediction, although lead molecule sampling scores a bit lower 498 on the latter metric. 499

A descriptor vector marking a position in the chemical space 500 may or may not translate to a chemically meaningful structure, 501 knowing that the initial vector is typically not a slightly 502 perturbed position vector of a real molecule but merely a 503 chemical space point associated with high predicted activity 504 according to a machine-learned, action mechanism-agnostic 505 model. However, the ACoVAE decoder process injecting 506 randomized latent vectors (see Section 2.1) may produce an 507 arbitrary number of SMILES strings based on a given chemical 508 space point. For each of the five considered chemical space 509 points of high predicted affinity, chemically meaningful 510 molecules were obtained (at a low success rate of 1.34% - 511 but this is merely an order of magnitude of the likelihood to 512 draw a random latent vector *i.e.*, "compatible" with the current 513 chemical space position). The complexity of the molecule that 514 the model is trying to generate is implicitly affecting the chance 515 to retrieve a valid structure. Since the model generates SMILES 516 strings, it must conform to a very specific grammar which is 517 intolerant to errors. Any misplaced character in the SMILES 518 sequence can render it incorrect and bring up an error—a well- 519 known problem in chemoinformatics. Without extensive 520 understanding of the chemical meaning behind a SMILES 521 string, it can be very difficult to correctly open and close 522 multiple rings to recreate valid structures with correct 523 aromaticity and stable behavior. This, in part, explains why 524 the model may be very successful in some parts of chemical 525 space and struggle more in other parts. A possible solution to 526 that problem would be the use of DeepSMILES<sup>61,62</sup> or 527 SELFIES<sup>63</sup> which use a simpler syntax eliminating the risks of 528 incorrect ring closures and parenthesis errors.

GTM landscapes identify zones enriched in actives, 530 nevertheless containing some inactives. The sampling is 531 performed using an ensemble of seeds generated from a 532 given GTM node. These seeds can occasionally be located in 533 the vicinity of inactives. In contrast, sampling from the most 534 active compound generates structures similar to this seed. This 535 explains the difference in the proportion active/inactive for 536 different seeds in Table 1.

Generated compounds were filtered to remove both 538 chemically inconsistent species (by CGRtools) and duplicates 539 and were compared to the initial training database (ChEMBL) 540 to compute the "novelty" rate which corresponds to the 541 percentage of valid unique generated compounds not 542 appearing in the training set of the model. Table 1 shows 543 that all generated compounds are novel. The trained SVR 544 model was used to estimate the  $pK_i$  values of the generated 545 compounds, which were then classified as actives or inactives 546 by using a threshold 7. As such, about half of the generated 547 compounds were predicted to be active. 548

Compounds predicted as inactives by the model were 549 filtered out. Generated compounds were compared to the GA- 550 optimized vectors used as input to the model. Results in Figure 551 f5



**Figure 5.** (A) Distribution of Tanimoto similarity calculated between sampled compounds and the ISIDA descriptors used for their sampling (obtained *via* SVR GA and lead molecule). (B) Distribution of predicted activities for inverse-SVR compounds, lead molecule sampled compounds, training compounds, and vectors optimized by GA. (C) Scatter plot with the *x*-axis being the Tanimoto similarity between the sampled compound and the GA vector and the *y*-axis, the difference in (calculated)  $pK_i$  between the inverse-SVR compounds and the original GA vector. The different colors correspond to the five different "seed" vectors used for the sampling procedure.

552 5A show that most compounds are very similar ( $T_c > 0.85/$ 553 0.90) to their "seed," meaning the model was able to 554 understand the information contained in the descriptor vector 555 and translate it in terms of SMILES. Given that the value 556 contained in the vectors may not be integers or that some of 557 the descriptor values may be incompatible, an average of  $T_c$  = 558 0.9 is a sign that the model was able to extract hidden 559 knowledge from the ISIDA descriptor and adapt it to a 560 chemically feasible structure. Some generated compounds 561 approach the activity values of the GA-optimized vectors as 562 shown in Figure 5B, although all active compounds have lower 563 pK<sub>i</sub>. Figure 5C shows the difference in predicted pK<sub>i</sub> between 564 the generated compounds (based on their actual D vectors) s65 and the "source" GA-optimized vectors  $\langle D \rangle$ , plotted against the Tanimoto coefficient  $T_c(\vec{D}, \langle \vec{D} \rangle)$ . Unsurprisingly, the SVR 566 QSAR models are neighborhood-behavior compliant: the 567 closer the source vector  $\langle \vec{D} \rangle$  remains to the actual compound 568 569 descriptor, the higher the likelihood to have the latter 570 predicted at high affinity levels—(virtual) activity cliffs  $_{571}$  notwithstanding (p $K_i$  shifts of 2 orders of magnitude may 572 occasionally happen for 90% similar descriptor vector pairs).

f5

The three most active compounds from ChEMBL, the three 573 inverse-SVR and three inverse-lead molecules predicted that 574 the most active were extracted and compared in terms of 575 structural similarity and  $pK_i$  values. The most active inverse- 576 SVR and inverse-lead compounds are structurally very similar 577 in terms of substructure counts but not necessarily in terms of 578 overall topology to the most active ChEMBL compounds, as 579 shown in Table 2. Similar substructures or features like 580 t2 quinoline, cyclopropane, peptide bonds, and fluoride atoms 581 appear in both ChEMBL and generated compounds-but they 582 may be interconnected in a different way. Sampling the 583 neighborhood of a given compound is likely to witness the 584 neural network return typical "building blocks" seen in those 585 compounds, all while recombining them and placing them in 586 original contexts. 587

3.3.2. "Inverse-GTM" Compounds. Inverse-GTM sampling, 588 in this case, gives better results in terms of validity and 589 uniqueness than inverse-SVR compounds. 590

Compounds generated from a GTM node vector consis- 591 tently tend to be projected into the same area they were 592 sampled from. This is not true of all compounds, a minority 593




Table 2. Most Active ChEMBL-Reported Compounds (A, B, C) against the ChEMBL1862 Target as Well as the Most Potent Structures Generated from the Different Seed Vectors<sup>a</sup>

<sup>a</sup>The numbers correspond to experimentally measured (for ChEMBL compounds) or predicted with SVR models  $pK_i$  values. <sup>b</sup>Compounds generated for the descriptor vector generated for molecule **A**, which is the highest affinity molecule (inverse-LEAD) with  $pK_i = 10.73$ .

594 being projected in different areas of chemical space—in 595 inactive-dominated zones (see Figure 6).

f6

f6

In inverse-GTM, random noise is also used to perturb the 597 input descriptor (GTM node vector), whereas inverse-SVR 598 compounds were strictly sampled on hand of the five 599 optimized descriptor vectors. Accordingly, the resulting 600 compounds are more diverse but less prone to score very 601 high predicted  $pK_i$  values as shown in Table 2. Rather than 602 focusing on recombination of fragments maximally contribu-603 ting to SVR-predicted  $pK_i$  values, the model incorporates 604 fragments of all training compounds occupying the vicinity of 605 the chosen "seed" vector. 3.3.3. "Inverse-SVR" and "Inverse-Lead" Versus "Inverse- 606 GTM". Sampling with inverse-SVR and inverse-lead has a 607 chance to return molecules predicted highly active, which is 608 not the case for compounds generated with inverse-GTM. This 609 can be explained by the fact that inverse-SVR (inverse-lead) 610 vectors served as the generation seed correspond to high 611 activity values, which is not the case for the GTM node 612 vectors. Inverse-GTM molecules have lower SVR-predicted 613  $pK_i$  values comparatively because "active" GTM landscape 614 areas were defined to harbor "actives" of  $pK_i \ge 7$ , and the 615 categorical nature of the landscape makes no further 616 distinction between submicromolars and subnanomolars. The 617 two methods produce active compounds, but molecules 618




Figure 6. Projection of the 100 most active compounds predicted by the SVR models, generated in different fashions. See caption of Figure 3 for landscape color coding. (A) Compounds were generated from "node" vectors obtained from node 1623. (B) Compounds were generated from "node" vectors obtained from node 1542. (C) Inverse-SVR compounds. (D) Inverse-lead compounds.

619 generated from inverse-SVR tend to be more focused on 620 specific chemical space zones predicted to stand for very high 621 affinity. Therefore, they reproduce structural features typical to 622 the few top actives—the "originality" mostly consisting in the 623 way in which these features (scaffolds, linkers) are reorganized 624 in the final structures. Inverse-GTM seeds tend by contrast to 625 stem from structurally less specific neighborhoods, generating a 626 more diverse set.

inverse-SVR inverse-Lead 5 inverse-GTM 4 Density 3 2 1 0 7.0 7.5 8.0 8.5 9.0 . 9.5 10.0 10.5 Predicted pKi

<sup>627</sup> Figure 7 confirms this trend as we see that the distribution of <sup>628</sup> activities of inverse-SVR and inverse-lead compounds has a tail

f7

**Figure 7.** Comparison between the distribution of (SVR-predicted) activities between inverse-SVR, inverse-lead, and inverse-GTM compounds.

in the very active regions, while the distribution of  $pK_i$  for 629 GTM-based compounds has a lower mean and is centered. 630

Interestingly, most of inverse-SVR compounds are projected 631 in the large active zone where inverse-GTM compounds were 632 sampled—even though the GTM-driven categorical QSAR is 633 based on other descriptors than the SVR approach. This is 634 additional proof that SVR-based and GTM-based models are 635 not fundamentally divergent in terms of prediction but merely 636 conflicting in terms of the specific definition of "actives" as 637 continuous *versus* categorical magnitudes. 638

As it follows from Figure 8, synthetic accessibility score for 639 f8 the generated compounds (inverse-SVR, inverse-lead, and 640 inverse-GTM) have on average a higher SA score than 641 ChEMBL compounds. According to this score, generated 642 structures are more difficult to synthetize than real ChEMBL 643 molecules. On the other hand, they are still in the range of 644 ChEMBL distribution (which goes up to 4.5–5) meaning that 645 generated structures are not synthetically unreachable and 646 therefore viable. The quantitative estimate druglikeness index 647 shows that on average, inverse-SVR and inverse-lead 648 compounds are of more interest for medicinal chemists than 649 inverse-GTM compounds.

3.3.4. Validation of Inverse-SVR and Inverse-Lead 651 Compounds Using Pharmacophore Modeling. Pharmaco- 652 phore models were trained using LigandScout<sup>41</sup> (4.4) to check 653 whether the generated compounds would also comply to the 654 ligand- and structure-based hypothetic binding patterns that 655 can be inferred on hand of current structure–activity data. 656 Both structure-based and ligand-based approaches were 657 applied in an effort to be as comprehensive as possible. The 658 compounds present in the training set of the SVR model (821 659 compounds) were used for ligand-based model training. 660




Figure 8. (A) Synthetic accessibility score for the four datasets calculated. (B) Quantitative estimate druglikeness index distribution for the three different datasets.

Table 3. Hits Found with Pharmacophore Models and Their Validation with Docking for Inverse-SVM (I–III) and Inverse-Lead (IV) Compounds

	Hits	calculated pKi / activity rank	Pharmacophore	Docking score (LeadIT)
Ι		9.82 3 <sup>rd</sup> most active	Model 1	-33.2
Π		9.34 / 16 <sup>th</sup> most active	Model 1	-31.4
III		9.18 25 <sup>th</sup> most active	Model 1	-23.27
IV		9.45 2 <sup>nd</sup> most active	Model 2	-31.8

<sup>661</sup> Ligand-based pharmacophores should reflect consensus <sup>662</sup> features in highly active binders. Therefore, a threshold of <sup>663</sup>  $pK_i \ge 9$  was considered here to define "actives," in contrast to <sup>664</sup> the default  $pK_i \ge 7$  defining "actives" in other contexts of this <sup>665</sup> work (GTM landscape, docking studies—*vide infra*). In <sup>666</sup> addition, only the inverse-SVR and inverse-lead compounds <sup>667</sup> with predicted  $pK_i \ge 9$  were screened. This subset of the initial <sup>668</sup> generated compounds contains 39 inverse-SVR molecules and <sup>669</sup> 8 inverse-lead compounds which makes 47 generated <sup>670</sup> compounds in total.

<sup>671</sup> For ligand-based pharmacophores, conformations for the <sup>672</sup> training set compounds were calculated using the pre-loaded <sup>673</sup> FAST parameters of the software. These settings returned a maximum of 25 conformations by compound. Ligand-based <sup>674</sup> pharmacophores were built and clustered by LigandScout.<sup>41</sup> <sup>675</sup> Pharmacophore models were calculated for two clusters <sup>676</sup> containing 78 and 5% (163 and 9 molecules, respectively) of <sup>677</sup> all training set actives (model 1 and model 2, respectively). <sup>678</sup> Different pharmacophore models were generated for each <sup>679</sup> cluster using sets of 5 to 10 molecules. <sup>680</sup>

Structure-based pharmacophores were built based on PDB  $_{681}$  crystal structures of human proto-oncogene tyrosine-protein  $_{682}$  kinase ABL1. 2HZI and 2CQG crystal structures were used to  $_{683}$  generate the shared pharmacophore model which was screened  $_{684}$  against the 47 generated compounds for which p $K_i > 9$  was  $_{685}$  predicted.




Figure 9. (A) Pharmacophore aligned with both PDB crystal structure ligands. (B) Shared pharmacophore model. (C) Selected inverse-SVR hits aligned with the pharmacophore model.


**3.3.4.1.** Ligand-Based Pharmacophore. The screening of 688 47 inverse-SVR and inverse-lead molecules "hidden" in a set of 689 328 inactive decoys selected from the training set inactives 690 allowed to understand if the two ligand-based pharmacophore 691 models were selective enough to primarily focus on putative 692 actives. If the considered pharmacophore models were 693 observed to be as likely to match inactive decoys, it may be 694 inferred that "matching" the pharmacophore model is no 695 reliable indicator of putative activity against CHEMBL1862 696 but merely that the ligand-based pharmacophore models are 697 too generic (easily matched by random compounds).

Model 1 and model 2 returned, respectively, three and one hits. The hits align well with the pharmacophore model, and most features match as shown in<sup>40</sup> Figures S4 and S5 in the rol Supporting Information. Table 3 shows that the four hits have roz relatively high ranking among the most actives, one of them ros being the third predicted most active inverse-SVR compound ro4 and another the second most active inverse-lead compound.

3.3.4.2. Structure-Based Pharmacophore Screening. The 705 706 shared pharmacophore model computed for two PDB 707 structures (2HZI and 2GQG) is mostly based on hydrophobic 708 interactions with one hydrogen bond donor and one hydrogen 709 bond acceptor as shown in Figure 9B. The ligands contained in 710 the PDB crystal structures are typically larger than inverse-SVR 711 molecules. However, Figure 9A shows that crystalized ligands 712 may include specific moieties not directly involved in binding. 713 VS with the shared pharmacophore returned eight hits (see 714 Table S2 in Supporting Information), four of which 715 correspond to those found with ligand-based pharmacophores 716 (Table 3). Notice that inverse-SVR compounds nicely match 717 the pharmacophore, all while being smaller than the PDB 718 ligands (see Figure 9C). These results show that the generated 719 compounds are not only predicted active by the SVR models 720 because they were optimized to do so but also fit the activity criteria of external validation methods like pharmacophore 721 models. The fact that these three compounds were found by 722 both methods and predicted highly active by the SVR model 723 724 indicates that these compounds may be good candidates for 725 further testing.

f

3.3.5. Validation of Inverse-SVR Compounds Using T27 Ligand-To-Protein Docking. In the docking challenge, both T28 LeadIT and S4MPLE were able to predict the correct binding T29 geometry of the native ligand of 2E2B (in protein-rigid T30 redocking mode), and both were seen to significantly prioritize T31 "actives" ( $pK_i > 7$ ), for LeadIT, the area under the ROC curve T32 obtained after redocking the 821 training set compounds (out T33 of which only 816 could be docked) was of 0.77. S4MPLE also performed reasonably well (ROC AUC = 0.69 after the 734 docking of 550 of the training set compounds, in random 735 order). At that point, a quantitative correlation of  $R^2 = 0.51$  736 between LeadIT and S4MPLE scores could be observed. 737 Unfortunately, neither the LeadIT score ( $R^2 = 0.21$ , over 816 738 redocked compounds) nor S4MPLE ( $R^2 = 0.16$  over the 550 739 ligands) can return docking scores that quantitatively correlate 740 with the experimental  $pK_i$  values. We refer the reader to the 741 Supporting Information section for a detailed analysis of the 742 relationships between docking scores and actual, respective 743 predicted pK<sub>i</sub> values. It was observed that 76% of the 744 experimentally confirmed training set actives  $(pK_i > 7)$  dock 745 with LeadIT scores below or equal to -30, whereas LeadIT 746 score  $\leq -25$  would retrieve 92% of them. Therefore, the 747 percentage of a library achieving LeadIT scores better (more 748 negative) than this order of magnitude is a first rough estimate 749 of how strongly CHEMBL-1862-focused that library is. Indeed, 750 these percentages are significantly higher within the mixed 751 collection of inverse-GTM and inverse-SVR leads (blue in 752 Figure 10) than within the random subset of ZINC random 753 f10 decoys (orange bars). It should be noticed that only two out of 754 three hits selected by pharmacophore models (molecules I, II, 755 and IV, Table 2) were validated in docking calculations as 756 actives: the LeadIT score for molecule III was larger than the 757 threshold of -25. The fact that the molecules I, II, and IV were 758



**Figure 10.** Percentages within the collection of inverse-GTM and inverse-SVR leads (blue) and the set or random ZINC decoys (orange) achieving LeadIt docking scores typical of experimentally validated actives of  $pK_i > 7$ .

759 found by both pharmacophore and docking methods as well as 760 predicted highly active by the SVR model indicates that these 761 compounds may be good candidates for further testing. We do 762 not exclude that application of a docking score correlating with 763 studied activity (*e.g.*, that reported by Ahmed *et al.*<sup>64</sup>) may 764 better validate generated molecules.

#### 4. CONCLUSIONS AND PERSPECTIVES

765 This article introduced a new type of architecture based on 766 state-of-the-art deep learning method which is capable, given a 767 descriptor type and successful training, to generate compounds 768 possessing wanted activity and structural features from "seed" 769 descriptor vectors—where the descriptor vectors are not 770 "latent" vectors themselves produced by some encoder 771 architecture but standard, state-of-the-art descriptors typically 772 used in QSAR (here, ISIDA fragment counts). This provides 773 an elegant solution for the inverse QSAR problem-the 774 inference of novel molecular structures matching model-775 predicted high activity zones of the descriptor space. Finding 776 descriptor "seeds" corresponding to aforementioned interest-777 ing zones has been herein addressed in two model-specific 778 ways: evolutionary search for D vectors corresponding to high 779 predicted affinity values ( $pK_i$ ) according to SVR models or D 780 vectors within the immediate neighborhood of GTM nodes 781 preferentially populated by active compounds. Additionally, 782 the descriptor vector generated for the highest affinity ligand 783 from the training set was also used as a seed. Selecting only 784 descriptor vectors associated with very high predicted affinity 785 values  $(pK_i)$  equal or close to the best ever values reported in 786 ChEMBL lead to inverse-SVR and inverse-lead molecules 787 being structurally related to already existing top-active 788 ChEMBL compounds—in the sense that they share significant 789 common substructures, all while preserving their global 790 originality. An external pharmacophore study performed on 791 inverse-SVR compounds shows that several molecules with 792 high predicted activity show good matches with existing active 793 molecules in terms of pharmacophores. Selecting the vectors 794 based on generative topographic mapping is focused on a 795 binary, class-based definition of activity, and inverse-GTM 796 molecules appear more diverse, all while predicted to have 797 remarkable  $pK_i$  values by the SVR models (better than 100 798 nM, but not yet close to the top-active ChEMBL compounds). 799 Original compounds of acceptable synthetic feasibility index 800 could be readily obtained. Therefore, the inverse QSAR 801 problem-fast discovery of original feasible compounds 802 specifically selected for being predicted active by a given 803 QSAR model—can be considered as conveniently solved, at 804 least for the (rather widely used) class of fragment-based 805 molecular descriptor-based QSAR models. Of course, the 806 ultimate promise of prospective discovery of experimentally 807 validated actives may only be kept if the "inversed" model lives 808 up to its promises in terms of prediction-but this is an 809 altogether different problem, which is not covered by the 810 present, purely methodological work. It is clearly not expected 811 to necessarily see inverse-QSAR de novo compounds automati-812 cally score well in docking if docking scores are decorrelated 813 from the QSAR-predicted affinity estimator. In particular, 814 fragment-count-based QSARs may overrate the importance of 815 given molecular fragments if the latter happen to appear by 816 chance only within the structures of actives, thus establishing 817 the mechanistically wrong shortcut "presence of key fragments  $818 \rightarrow$  activity" simply because inactive counterexamples contain-819 ing the same fragments in a different mutual configuration

were not found at the training stage. ACoVAE-based 820 approaches may, as seen in this work, readily suggest structures 821 issued by recombining such key fragments-guaranteed to 822 achieve high ratings by the parent QSAR model but not sure to 823 still feature a global pharmacophore compatible with the target. 824 The goal of this work was to present genuine solutions for the 825 QSAR inversion problem based on "classical" fragment 826 descriptors rather than on DNN-specific latent space vectors. 827 Technically, this was a success, but it also clearly reveals that 828 QSAR inversion *alone* is too risky a path to take in drug design: 829 the actual pursuit of the synthesis efforts of sometimes 830 challenging (but-granted-novel) structures may or may not 831 pay, given the intrinsically incomplete and error-prone nature 832 of QSAR models. However, if inverse QSAR is coupled with 833 orthogonal activity prediction techniques, as done here, it can 834 be observed that many of compounds alleged to be active by 835 the initial QSAR models fail to pass the additional, 836 independent activity assessment tests (pharmacophore match- 837 ing, docking). This is no surprise because the consensus rate of 838 chemoinformatics predictors based on premises as radically 839 different as 2D-QSAR, pharmacophore screening and docking 840 are typically very low. Nevertheless, we were successful in 841 discovering some de novo structures which did pass the latter 842 tests. This shows that the exploration of the initial inverse- 843 QSAR-relevant chemical space is sufficient to visit areas in 844 which not only the original QSAR model but also the 845 alternative approaches indicate that biological activity is likely, 846 pending experimental validation. 847

ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge at 850 https://pubs.acs.org/doi/10.1021/acs.jcim.2c01086. 851

Detailed description of neural network architecture and 852 some complementary results of QSAR and pharmaco- 853 phore modeling (PDF) 854

848

849

855

856

861

#### AUTHOR INFORMATION

#### Corresponding Author

Alexandre Varnek – Laboratory of Chemoinformatics, UMR 857 7140 University of Strasbourg/CNRS, 67000 Strasbourg, 858 France; orcid.org/0000-0003-1886-925X; 859 Email: varnek@unistra.fr 860

#### Authors

- William Bort Laboratory of Chemoinformatics, UMR 7140 862 University of Strasbourg/CNRS, 67000 Strasbourg, France 863 Daniyar Mazitov – Laboratory of Chemoinformatics and 864
- Molecular Modeling, A. M. Butlerov Institute of Chemistry, Kazan Federal University, 420008 Kazan, Russia
- Dragos Horvath Laboratory of Chemoinformatics, UMR 7140 University of Strasbourg/CNRS, 67000 Strasbourg, 868 France; © orcid.org/0000-0003-0173-5714 869
- Fanny Bonachera Laboratory of Chemoinformatics, UMR8707140 University of Strasbourg/CNRS, 67000 Strasbourg,<br/>France871
- Arkadii Lin Laboratory of Chemoinformatics, UMR 7140
   873
   University of Strasbourg/CNRS, 67000 Strasbourg, France
   874
- Gilles Marcou Laboratory of Chemoinformatics, UMR 7140 875 University of Strasbourg/CNRS, 67000 Strasbourg, France; 876 orcid.org/0000-0003-1676-6708 877

- 878 Igor Baskin Department of Material Science and
- Engineering, Technion—Israel Institute of Technology,
  3200003 Haifa, Israel
- 881 Timur Madzhidov Laboratory of Chemoinformatics and
- 882 Molecular Modeling, A. M. Butlerov Institute of Chemistry,
- 883 Kazan Federal University, 420008 Kazan, Russia;

885 Complete contact information is available at:

886 https://pubs.acs.org/10.1021/acs.jcim.2c01086

#### 887 Notes

888 The authors declare no competing financial interest.

889 Data and Software Availability: Developed code is available at
890 the GitHub storage of the Laboratory of Chemoinformatics:
891 https://github.com/Laboratoire-de-Chemoinformatique/
892 ACoVAE. The data used for the model training and validation
893 are available at https://entrepot.recherche.data.gouv.fr/
894 dataset.xhtml?persistentId=doi:10.57745/ILWSLF.

#### 895 **ACKNOWLEDGMENTS**

896 The High Performance Computing (HPC) Center of the 897 Strasbourg University is acknowledged for technical support.

#### 898 **ABBREVIATIONS**

899 ACoVAE, attention-based conditional variational autoencoder; 900 DNN, deep neural network; GA, genetic algorithm; GTM, 901 generative topographic map; QSA/PR, quantitative structure— 902 activity/property relationships; SVR, support vector regres-903 sion; VS, virtual screening

#### 904 **REFERENCES**

905 (1) Dudek, A.; Arodz, T.; Galvez, J. Computational Methods in
906 Developing Quantitative Structure-Activity Relationships (QSAR): A
907 Review. Comb. Chem. High Throughput Screening 2006, 9, 213–228.
908 (2) Hansch, C. H.; Leo, A. J. Exploring QSAR: Fundamentals and
909 Applications in Chemistry and Biology; American Chemical Society,
910 1995; Vol. 1.

911 (3) Korotcov, A.; Tkachenko, V.; Russo, D.; Ekins, S. Comparison of 912 Deep Learning With Multiple Machine Learning Methods and 913 Metrics Using Diverse Drug Discovery Data Sets. *Mol. Pharm.* **2017**, 914 *14*, 4462–4475.

915 (4) Varnek, A.; Baskin, I. Machine Learning Methods for Property 916 Prediction in Chemoinformatics: Quo Vadis? *J. Chem. Inf. Model.* 917 **2012**, *52*, 1413–1437.

918 (5) Jin, Y.; Wang, H.; Sun, C. *Introduction to Machine Learning*; 919 Springer International Publishing, 2021; Vol. 975.

920 (6) Smola, A.; Schölkopf, B. A tutorial on support vector regression.
921 Stat. Comput. 2004, 14, 199–222.

922 (7) Breiman, L. Random Forests. Mach. Learn. 2001, 45, 5-32.

923 (8) Skvortsova, M.; Fedyaev, K.; Palyulin, V.; Zefirov, N. Inverse 924 Structure–Property Relationship Problem for the Case of a 925 Correlation Equation Containing the Hosoya Index. *Dokl. Chem.* 926 **2001**, 379, 191–195.

927 (9) Skvortsova, M.; Stankevich, I.; Zefirov, N. Generation of 928 molecular structures of polycondensed benzenoid hydrocarbons using 929 the randic index. *J. Struct. Chem.* **1992**, 33, 416–422.

(10) Skvortsova, M.; Baskin, I.; Slovokhotova, O.; Palyulin, V.;
Palyulin, V.;
Zefirov, N. Inverse Problem in QSAR/QSPR Studies for the Case of
Topological Indices Characterizing Molecular Shape (Kier Indices). J.
Chem. Inf. Comput. Sci. 1993, 33, 630–634.

(11) Lin, A.; Horvath, D.; Marcou, G.; Beck, B.; Varnek, A. Multitask generative topographic mapping in virtual screening. *J. Comput.*-*Aided Mol. Des.* 2019, 33, 331–343.

(12) Ripphausen, P.; Nisius, B.; Bajorath, J. State-of-the-art in 937
ligand-based virtual screening. *Drug Discovery Today* 2011, 16, 372–938
376. 939

(13) Hartenfeller, M.; Zettl, H.; Walter, M.; Rupp, M.; Reisen, F.; 940 Proschak, E.; Weggen, S.; Stark, H.; Schneider, G. DOGS: Reaction- 941 Driven de novo Design of Bioactive Compounds. *PLoS Comput. Biol.* 942 **2012**, *8*, No. e1002380. 943

(14) Mauser, H.; Guba, W. Recent developments in de novo design 944 and scaffold hopping. *Curr. Opin. Drug Discovery Dev.* **2008**, *11*, 365–945 374. 946

(15) Hartenfeller, M.; Proschak, E.; Schüller, A.; Schneider, G. 947
Concept of Combinatorial De Novo Design of Drug-like Molecules 948
by Particle Swarm Optimization. *Chem. Biol. Drug Des.* 2008, 72, 16–949
26. 950

(16) Sattarov, B.; Baskin, I.; Horvath, D.; Marcou, G.; Bjerrum, E.; 951 Varnek, A. De Novo Molecular Design by Combining Deep 952 Autoencoder Recurrent Neural Networks with Generative Topo-953 graphic Mapping. J. Chem. Inf. Model. **2019**, 59, 1182–1196. 954

(17) Gómez-Bombarelli, R.; Wei, J.; Duvenaud, D.; Hernández- 955 Lobato, J.; Sánchez-Lengeling, B.; Sheberla, D.; Aguilera-Iparraguirre, 956 J.; Hirzel, T.; Adams, R.; Aspuru-Guzik, A. Automatic Chemical 957 Design Using a Data-Driven Continuous Representation of 958 Molecules. *ACS Cent. Sci.* **2018**, *4*, 268–276. 959

(18) Zhou, Z.; Kearnes, S.; Li, L.; Zare, R.; Riley, P. Optimization of 960 Molecules via Deep Reinforcement Learning. *Sci. Rep.* **2019**, *9*, 10752. 961 (19) Segler, M. H. S.; Kogej, T.; Tyrchan, C.; Waller, M. P. 962 Generating Focused Molecule Libraries for Drug Discovery with 963

Recurrent Neural Networks. ACS Cent. Sci. 2018, 4, 120–131. 964 (20) Olivecrona, M.; Blaschke, T.; Engkvist, O.; Chen, H. Molecular 965

De Novo Design through Deep Reinforcement Learning. J. Cheminf. 966 2017, 9, 48. 967

(21) Prykhodko, O.; Johansson, S.; Kotsias, P.; Arús-Pous, J.; 968 Bjerrum, E.; Engkvist, O.; Hongming, C. A de novo molecular 969 generation method using latent vector based generative adversarial 970 network. *J. Cheminf.* **2019**, *11*, 74. 971

(22) Arús-Pous, J.; Patronov, A.; Bjerrum, E.; Tyrchan, C.; 972 Reymond, J.-L.; Hongming, C.; Engkvist, O. SMILES-based deep 973 generative scaffold decorator for de-novo drug design. *J. Cheminf.* 974 **2020**, 12, 38. 975

(23) Cova, T.; Pais, A. Deep Learning for Deep Chemistry: 976
 Optimizing the Prediction of Chemical Patterns. *Front. Chem.* 2019, 977
 7, 809. 978

(24) Gupta, M. K.; Gupta, S.; Rawal, R. Impact of Artificial Neural 979 Networks in QSAR and Computational Modeling. In *Artificial Neural* 980 *Network for Drug Design, Delivery and Disposition*; Academic Press, 981 2016; pp 153–179. 982

(25) Mitchell, J. B. O. Machine learning methods in chemo- 983 informatics. Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2014, 4, 468– 984 481. 985

(26) Fjodorova, N.; Vračko, M.; Jezierska, A.; Novič, M. Counter 986 propagation artificial neural network categorical models for prediction 987 of carcinogenicity for non-congeneric chemicals. *SAR QSAR Environ.* 988 *Res.* **2010**, *21*, 57–75. 989

(27) Ajmani, S.; Viswanadhan, V. N. A Neural Network-Based 990 QSAR Approach for Exploration of Diverse Multi-Tyrosine Kinase 991 Inhibitors and its Comparison with a Fragment- Based Approach. 992 *Curr. Comput.-Aided Drug Des.* **2013**, *9*, 482–490. 993

(28) Myint, K.-Z.; Wang, L.; Tong, Q.; Xie, X. Molecular 994 Fingerprint-Based Artificial Neural Networks QSAR for Ligand 995 Biological Activity Predictions. *Mol. Pharmaceutics* **2012**, *9*, 2912–996 2923. 997

(29) Rana, A.; Rawat, A.; Bijalwan, A.; Bahuguna, H. Application of 998 Multi Layer (Perceptron) Artificial Neural Network in the Diagnosis 999 System: A Systematic Review. In 2018 International Conference on 1000 Research in Intelligent and Computing in Engineering (RICE); IEEE, 1001 2018; pp 1–6. 1002

(30) Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. Neural Networks in 1003 Building QSAR Models. In *Artificial Neural Networks: Methods and* 1004 1005 *Applications*; Livingstone, D. J., Ed.; Humana Press, 2009; pp 133–1006 154.

1007 (31) Sabando, M. V.; Ponzoni, I.; Milios, E.; Soto, A. Using 1008 molecular embeddings in QSAR modeling: Does it make a difference? 1009 *Briefings Bioinf.* **2022**, *23*, bbab365.

1010 (32) Muratov, E. N.; Bajorath, J.; Sheridan, R.; Tetko, I.; Filimonov, 1011 D.; Poroikov, V.; Oprea, T.; Baskin, I.; Varnek, A.; Roitberg, A.; 1012 Isayev, O.; Curtalolo, S.; Fourches, D.; Cohen, Y.; Aspuru-Guzik, A.; 1013 Winkler, D.; Agrafiotis, D.; Cherkasov, A.; Tropsha, A. QSAR without 1014 borders. *Chem. Soc. Rev.* **2020**, *49*, 3525–3564.

1015 (33) Sousa, T.; Correia, J.; Pereira, V.; Rocha, M. Generative Deep 1016 Learning for Targeted Compound Design. *J. Chem. Inf. Model.* **2021**, 1017 *61*, 5343–5361.

1018 (34) Weininger, D.; Weininger, A.; Weininger, J. Algorithm for 1019 generation of unique SMILES notation. J. Chem. Inf. Comput. Sci. 1020 **1989**, 29, 97–101.

1021 (35) Kotsias, P.-C.; Arús-Pous, J.; Chen, C.; Engkvist, O.; Tyrchan, 1022 C.; Bjerrum, E. Direct steering of de novo molecular generation with 1023 descriptor conditional recurrent neural networks. *Nat. Mach. Intell.* 1024 **2020**, *2*, 254–265.

1025 (36) Ucak, U. V.; Ashyrmamatov, I.; Lee, J. Reconstruction of 1026 lossless molecular representations, SMILES and SELFIES, from 1027 fingerprints. *ChemRxiv* **2022**, DOI: 10.26434/chemrxiv-2022-tqv76-1028 v2.

1029 (37) Varnek, A.; Fourches, D.; Horvath, D.; Klimchuk, O.; Gaudin, 1030 C.; Vayer, P.; Solov'ev, V.; Hoonakker, F.; Tetko, I.; Marcou, G. 1031 ISIDA—Platform for Virtual Screening Based on Fragment and 1032 Pharmacophoric Descriptors. *Curr. Comput.-Aided Drug Des.* **2008**, *4*, 1033 191–198.

1034 (38) Varnek, A.; Fourches, D.; Solov'ev, V.; Klimchuk, O.; Ouadi, 1035 A.; Billard, I. Successful "In Silico" Design of New Efficient Uranyl 1036 Binders. *Solvent Extr. Ion Exch.* **200**7, *25*, 433–462.

1037 (39) Sidorov, P.; Gaspar, H.; Marcou, G.; Varnek, A.; Horvath, D. 1038 Mappability of drug-like space: Towards a polypharmacologically 1039 competent map of drug-relevant compounds. *J. Comput.-Aided Mol.* 1040 *Des.* **2015**, 29, 1087–1108.

1041 (40) Ruggiu, F.; Marcou, G.; Varnek, A.; Horvath, D. ISIDA 1042 Property-labelled fragment descriptors. *Mol. Inf.* **2010**, *29*, 855–868. 1043 (41) Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores 1044 Derived from Protein-Bound Ligands and Their Use as Virtual 1045 Screening Filters. *J. Chem. Inf. Model.* **2005**, *45*, 160–169.

1046 (42) *LeadIT*; BioSolveIT GmbH: Sankt Augustin, Germany, 2022. 1047 www.biosolveit.de.

1048 (43) Hoffer, L.; Chira, C.; Marcou, G.; Varnek, A.; Horvath, D. 1049 S4MPLE—Sampler for Multiple Protein-Ligand Entities: Method-1050 ology and Rigid-Site Docking Benchmarking. *Molecules* **2015**, *20*, 1051 8997–9028.

1052 (44) Mehta, S.; Ghazvininejad, M.; Iyer, S.; Zettlemoyer, L.; 1053 Hajishirzi, H. DeLighT: Deep and Light-weight Transformer. **2020**, 1054 arxiv:2008.00623. arXiv preprint.

1055 (45) Vaswani, A.; Shazeer, N.; Parmar, N.; Uszkoreit, J.; Jones, L.; 1056 Gomez, A.; Kaiser, L.; Polosukhin, I. Attention Is All You Need. 31st 1057 Conference on Neural Information Processing Systems 2017, 2017; pp 1058 5999–6009.

1059 (46) Lin, Z.; Winata, G. I.; Xu, P.; Liu, Z.; Fung, P. Variational 1060 Transformers for Diverse Response Generation. **2020**, 1061 arxiv:2003.12738. arXiv preprint.

1062 (47) Davidson, T. R.; Falorsi, L.; De Cao, N.; Kipf, T.; Tomczak, J. 1063 M. Hyperspherical variational auto-encoders. *34th Conference on* 1064 *Uncertainty in Artificial Intelligence 2018, UAI 2018,* 2018; Vol. 2, pp 1065 856–865.

1066 (48) De Cao, N.; Aziz, W. The Power Spherical Distribution. **2020**, 1067 arxiv:2006.04437. arXiv preprint.

1068 (49) Mehta, S.; Ghazvininejad, M.; Iyer, S.; Zettlemoyer, L.; 1069 Hajishirzi, H. DeLighT: Deep and Light-weight Transformer. **2021**, 1070 arXiv:2008.00623. arXiv preprint.

1071 (50) Hendrycks, D.; Gimpel, K. Gaussian Error Linear Units 1072 (GELUs). **2016**, arxiv:1606.08415. arXiv preprint. (51) Chieng, H. H.; Wahid, N.; Pauline, O.; Perla, S. R. K. Flatten-t 1073 swish: A thresholded relu-swish-like activation function for deep 1074 learning. *Int. J. Adv. Intell. Inform.* **2018**, *4*, 76–86. 1075

(52) Horvath, D.; Brown, J.; Marcou, G.; Varnek, A. An 1076 Evolutionary Optimizer of libsvm Models. *Challenges* **2014**, *5*, 450–1077 472. 1078

(53) Bishop, C. M.; Svensen, M.; Williams, C. GTM: The 1079 Generative Topographic Mapping. *Neural Comput.* **1998**, *10*, 215–1080 234. 1081

(54) Dragos, H.; Gilles, M.; Alexandre, V. Predicting the 1082 Predictability: A Unified Approach to the Applicability Domain 1083 Problem of QSAR Models. J. Chem. Inf. Model. **2009**, 49, 1762–1776. 1084

(55) Horvath, D.; Jeandenans, C. Neighborhood behavior of in silico 1085 structural spaces with respect to in vitro activity spaces—A novel 1086 understanding of the molecular similarity principle in the context of 1087 multiple receptor binding profiles. *J. Chem. Inf. Comput. Sci.* **2003**, *43*, 1088 680–690. 1089

(56) Casciuc, I.; Zabolotna, Y.; Horvath, D.; Marcou, G.; Bajorath, 1090 J.; Varnek, A. Virtual Screening with Generative Topographic Maps: 1091 How Many Maps Are Required? *J. Chem. Inf. Model.* **2019**, *59*, 564–1092 572. 1093

(57) Nugmanov, R. I.; Mukhametgaleev, R.; Akhmetshin, T.; 1094 Gimadiev, T.; Afonina, V.; Madzhidov, T.; Varnek, A. CGRtools: 1095 Python Library for Molecule, Reaction, and Condensed Graph of 1096 Reaction Processing. J. Chem. Inf. Model. **2019**, 59, 2516–2521. 1097

(58) Ertl, P.; Schuffenhauer, A. Estimation of synthetic accessibility 1098 score of drug-like molecules based on molecular complexity and 1099 fragment contributions. J. Cheminf. **2009**, 1, 8.

(59) Kosugi, T.; Ohue, M. Quantitative Estimate Index for Early- 1101 Stage Screening of Compounds Targeting Protein-Protein Inter- 1102 actions. Int. J. Mol. Sci. 2021, 22, 10925.

(60) ChemAxon Standardizer, Version 5.12; ChemAxon, Ltd.: 1104 Budapest, Hungary, 2012.

(61) O'Boyle, N.; Dalke, A. DeepSMILES: An Adaptation of 1106 SMILES for Use in Machine-Learning of Chemical Structures. 1107 *ChemRxiv* 2018, DOI: 10.26434/chemrxiv.7097960.v1. 1108

(62) Berenger, F.; Tsuda, K. Molecular generation by Fast Assembly 1109 of (Deep)SMILES fragments. J. Cheminf. **2021**, 13, 88.

(63) Krenn, M.; Häse, F.; Nigam, A.; Friederich, P.; Aspuru-Guzik, 1111 A. Self-referencing embedded strings (SELFIES): A 100% robust 1112 molecular string representation. *Mach. Learn.: Sci. Technol.* **2020**, *1*, 1113 045024. 1114

(64) Ahmed, S.; Prabahar, A. E.; Saxena, A. K. Molecular docking- 1115 based interactions in QSAR studies on Mycobacterium tuberculosis 1116 ATP synthase inhibitors. *SAR QSAR Environ. Res.* **2022**, *33*, 289–305. 1117